Drug Class Review: TARGETED IMMUNE MODULATORS – UPDATE 3

Description

1. How do included drugs compare in their efficacy and long-term effectiveness for alleviating symptoms and stabilizing the disease in patients with rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, or plaque psoriasis? 2. What are the comparative incidence and severity of harms associated with the use of these drugs? 3. Do the included drugs differ in effectiveness or harms in the following subgroups: ? Different genders, or different racial, age or socioeconomic groups? ? Patients with co-morbidities? ? Patients taking other commonly prescribed drugs? ? Patients with early aggressive vs. persistent rheumatoid arthritis

Details

Duration 01/03/2011 - 31/01/2012
Funding Sonstige
Department

Department for Evidence-based Medicine and Clinical Epidemiology

Principle investigator for the project (Danube University Krems) Univ.-Prof. Dr. Gerald Gartlehner, MPH
Project members Evelyn Auer Mag. Christina Kien Michaela Strobelberger, MA Dr. Kylie Thaler
Back to top

 

To Glossary

This website uses cookies to improve your user experience and for analytical purposes for optimizing our systems. By clicking on „OK" or continuing to browse the site, you are agreeing to the use of cookies. More information concerning privacy policy and data protection official.

OK